Table I.
Treatment b | CIA/Total c | Day Onset d | Max. Score e | Average score f | CS g |
---|---|---|---|---|---|
PBS | 10/10 | 27.8 ± 1.6 | 10 | 7.2 ± 0.78 | 50.4 ± 7.11 |
H696CD4+ T cells and IgG | 4/10 | 33 ± 5.35 | 4 | 1.44 ± 0.65* † | 7.78 ± 4.65* † |
H696CD4+ T cells and anti-IL-4 | 8/8 | 26.71 ± 2.29 | 8 | 3.62 ± 0.96 | 34.87 ± 11.09 |
H696CD4+ T cells and anti-TGF-β | 8/8 | 27.25 ± 2.43 | 12 | 5.75 ± 0.86 | 49.37 ± 10.13 |
Arthritis was induced in DBA/1 mice with 100 μg bovine CII in complete Freund’s adjuvant on day 0.
Salmonella-CFA/1 primed CD4+ T cells were adoptively transferred to mice with induced arthritis on day 15. Intra-peritoneal mAb treatments were initiated on day of transfer, then weekly for a total of four doses (1 mg total of mAb/mouse).
Number of mice with CIA /total in a group for 43 days after CII challenge.
Mean day ± SEM of first symptoms onset in diseased mice only.
Maximum score in group in entire observation period.
Average clinical score per group on day 43 post-induction (end of observation period) calculated as sum of individual scores divided by the number of mice in group ± SEM.
P < 0.005 as compared to PBS group;
P < 0.05 as compared to anti-IL-4 or anti-TGF-β mAb treated group.
Cumulative scores (CS) calculated as all scores during the period of observation divided by number of mice in each group.
P < 0.005 as compared to PBS and anti-TGF-β treated groups;
P < 0.05 as compared to anti-IL-4 treated group.